2022 American Transplant Congress
Diabetes Mellitus and Blood Glucose Variability Increases the 30-day Readmission Rate After Kidney Transplantation
*Purpose: The 30-day readmission rate is a surrogate metric of quality of care and mortality after kidney transplantation. Diabetes and observations of glucose variability during…2022 American Transplant Congress
Cardiovascular Outcomes of Kidney Transplant Recipients Receiving Belatacept Compared to a Matched Tacrolimus
*Purpose: Tacrolimus (TAC), a calcineurin inhibitor (CNI), is the backbone of maintenance immunosuppression in kidney transplant recipients (KTR) but has been associated with cardiovascular (CV)…2022 American Transplant Congress
Glucose Variability in Kidney Transplantation: Pre-Transplant and Post-Transplant Continuous Glucose Monitoring
*Purpose: Continuous glucose monitoring (CGM) provides a 24-hour view of glucose values and information on glycemic variability and additional indices such as the glucose management…2022 American Transplant Congress
Epidemiology of Post Transplant Diabetes Mellitus
Renal Medicine Department, The Royal Hospital, Bausher, Oman
*Purpose: Diabetes mellitus (DM) is a common non-communicable disease and have serious metabolic complications that contribute to death, major cardiovascular events, organs failure, and increased…2022 American Transplant Congress
Sodium-Glucose Co-Transporter 2 Inhibitors; Short-Term Outcome in Diabetic Kidney Transplant Recipients
*Purpose: The idea of using SGLT2i in kidney transplant recipients (KTR) is a legitimate one after the recent encouraging data for their use in other…2022 American Transplant Congress
Outcomes of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists in Diabetic Kidney Transplant Recipients
*Purpose: The impact of the new glucose lowering therapies, sodium-glucose cotransporter 2 inhibitors (SGLT2i) and Glucagon-like peptide-1 receptor agonists (GLP-1RA), on managing patients with type…2022 American Transplant Congress
Safety and Efficacy of GLP-1 Agonists in Solid Organ Transplant Recipients
Pharmacy, Tampa General Hospital, Tampa, FL
*Purpose: Glucagon-like peptide-1 receptor agonists (GLP-1 RA) have been shown to improve glycemic control, obesity, and cardiovascular disease in the general population. The safety and…2022 American Transplant Congress
Impact of a Pharmacy-Led Post-Transplant Diabetes Mellitus Clinic in Solid Organ Transplant Recipients
*Purpose: To evaluate the impact of a pharmacy-led post-transplant diabetes mellitus (DM) clinic.*Methods: This retrospective chart review from 08/01/20 to 6/30/21 evaluated adult kidney transplant…2022 American Transplant Congress
Everolimus versus Mycophenolate in Simultaneous Pancreas and Kidney Transplantation: Progression of Diabetic Retinopathy in a Prospective Randomized Trial
*Purpose: mTOR inhibitors are known for their antiangiogenic effect. We compared the impact of everolimus (E) and mycophenolic acid (MPA) on the course of diabetic…2022 American Transplant Congress
Evaluation of GLP-1 Receptor Agonist Use in the Solid Organ Transplant Population
Pharmacy, University of Colorado Hospital, Aurora, CO
*Purpose: The purpose of this study was to evaluate the utilization of and identify opportunities to optimize the use of glucagon-like peptide-1 receptor agonist (GLP-1…
- 1
- 2
- 3
- …
- 7
- Next Page »